Lunit Launches Enhanced Lunit INSIGHT CXR4, Secures CE MDR Certification for Expanded AI Capabilities

Next-generation AI solution introduces new clinical features and broader disease detection for chest X-rays

SEOUL, South Korea, May 29, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the official launch and CE certification under the Medical Device Regulation (MDR) of Lunit INSIGHT CXR4, its next-generation chest X-ray analysis solution.
Lunit INSIGHT CXR4 is a comprehensive AI solution for chest imaging, designed to support radiologists across a wide range of clinical scenarios. It leverages advanced AI to detect 12 types of thoracic abnormalities—including lung nodules, pneumonia, and pneumothorax—expanding its diagnostic capabilities to include additional findings such as acute bone fractures. Trained on large-scale real-world datasets, the upgraded solution delivers improved diagnostic accuracy while supporting early detection of critical thoracic diseases.

In addition to expanded disease detection, Lunit INSIGHT CXR4 introduces several new features designed to enhance clinical workflow and diagnostic support:

• Normal Flagging: While other solutions may flag cases as normal simply due to the absence of detectable findings, CXR4 takes a more advanced approach — leveraging an AI engine trained on over 1,200,000 chest X-rays to proactively identify and confirm truly normal cases. Backed by a high negative predictive value (NPV) of 99.5%, CXR4 can reliably distinguish low-risk exams. For these high-confidence normal cases, the system automatically generates structured reports, helping radiologists reduce reading time and streamline workflow without compromising diagnostic safety. 
• Current-Prior Comparison: Compares a patient’s current chest X-ray with previous images to detect disease progression or improvement over time, enabling more informed clinical decisions. The latest version also supports nodule comparisons, offering added value for lung cancer screening and follow-up evaluations.
• New Finding — Acute Bone Fracture Detection: Enables detection of recent traumatic fractures within the chest X-ray field of view. By identifying subtle fractures that are easy to miss, CXR4 helps reduce interpretation time and improve diagnostic accuracy, particularly in busy clinical environments.

With CE MDR certification, Lunit is now positioned to deploy INSIGHT CXR4 across Europe—offering enhanced diagnostic confidence and workflow efficiency for radiologists managing high imaging volumes.

"With Lunit INSIGHT CXR4, we’ve gone beyond expanding detection—we’ve focused on what truly helps clinicians in their day-to-day workflow,” said Brandon Suh, CEO of Lunit. “Features like active normal flagging and current-prior comparison are designed to reduce reading time and improve triage confidence, especially in high-volume settings. CE MDR certification is a key step toward broader adoption, and we’re committed to bringing CXR4 to more hospitals worldwide.”

With CE MDR certification now in place, Lunit is preparing to pursue additional regulatory approvals to make CXR4 available in more regions. The company aims to further integrate its AI solutions into clinical workflows across diverse healthcare systems.

CE MDR is the EU’s enhanced regulatory standard for medical devices, ensuring stricter standards for safety, performance, and clinical validation.

If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.